View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 18, 2022

George Medicines to analyse three-in-one hypertension pill in UK trial

The trial will assess the efficacy and safety of GMRx2 against dual cocktails of the same components for 12 weeks.

George Medicines has announced the launch of a clinical trial to evaluate its three-in-one, low-dose combination pill GMRx2 in individuals with high blood pressure (hypertension) in the UK.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

GMRx2, which is in late-stage development, comprises low doses of telmisartan, amlodipine and indapamide, which are the common hypertension therapeutics.

The investigational pill is claimed to boost adherence to therapy while lowering side effects.

The trial will be carried out in partnership with academic clinical research organisation, ICTU Global, at Imperial College London, UK.

It will compare GMRx2’s efficacy and safety against dual cocktails of the same components for a period of 12 weeks. 

The international trial is expected to enrol nearly 500 subjects from hospitals and GP practices in England.

Currently, 1,000 subjects are being enrolled across global trial centres including the US and Australia.

The latest trial comes after previous successful studies, where the low-dose triple combo substantially outperformed standard hypertension therapies without further side effects.

With the Phase III trial being the concluding stage of development, results are expected to support a regulatory filing to obtain approval.

George Medicines CEO Stefan König said: “This unique, three-in-one hypertension pill has the potential to substantially increase efficacy and improve adherence to treatment while minimising side effects. 

“At George Medicines, we believe affordable, single-pill combinations of existing medicines could help patients to better manage non-communicable diseases such as hypertension, cardiovascular disease and type 2 diabetes.”

A key avoidable risk factor for vascular dementia, heart and kidney disease in the UK, hypertension causes more than 50% of all heart attacks and strokes. This costs the National Health Service (NHS) more than £2.1bn every year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena